rs3814113
|
|
A |
0.820 |
GeneticVariation |
GWASDB |
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.
|
23544013 |
2013 |
rs3814113
|
|
A |
0.820 |
GeneticVariation |
GWASCAT |
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.
|
23544013 |
2013 |
rs3814113
|
|
|
0.820 |
GeneticVariation |
GWASCAT |
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.
|
23535730 |
2013 |
rs3814113
|
|
|
0.820 |
GeneticVariation |
BEFREE |
To assess the potential implications of microRNAs in ovarian cancer, we investigated the associations between microRNA expression and seven ovarian cancer risk variants discovered from genome-wide association studies (GWAS), namely, rs3814113 on 9p22.2, rs2072590 on 2q31, rs2665390 on 3q25, rs10088218, rs1516982, rs10098821 on 8q24.21 and rs2363956 on 19p13.
|
22235027 |
2012 |
rs3814113
|
|
|
0.820 |
GeneticVariation |
BEFREE |
A genome-wide association study recently identified an association between the rare allele of the single-nucleotide polymorphism (SNP) rs3814113 (ie, the C allele) at 9p22.2 and decreased risk of ovarian cancer for women in the general population.
|
21169536 |
2011 |
rs3814113
|
|
T |
0.820 |
GeneticVariation |
GWASCAT |
The most significant SNP (rs3814113; P = 2.5 x 10(-17)) was genotyped in a further 2,670 ovarian cancer cases and 4,668 controls, confirming its association (combined data odds ratio (OR) = 0.82, 95% confidence interval (CI) 0.79-0.86, P(trend) = 5.1 x 10(-19)).
|
19648919 |
2009 |
rs4691139
|
|
G |
0.800 |
GeneticVariation |
GWASCAT |
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.
|
28346442 |
2017 |
rs17631303
|
|
G |
0.800 |
GeneticVariation |
GWASDB |
In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4 × 10(-8), HR = 1.27, 95% CI: 1.17-1.38) and 4q32.3 (rs4691139, P = 3.4 × 10(-8), HR = 1.20, 95% CI: 1.17-1.38).
|
23544013 |
2013 |
rs17631303
|
|
G |
0.800 |
GeneticVariation |
GWASCAT |
In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4 × 10(-8), HR = 1.27, 95% CI: 1.17-1.38) and 4q32.3 (rs4691139, P = 3.4 × 10(-8), HR = 1.20, 95% CI: 1.17-1.38).
|
23544013 |
2013 |
rs183211
|
|
A |
0.800 |
GeneticVariation |
GWASDB |
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.
|
23544013 |
2013 |
rs183211
|
|
A |
0.800 |
GeneticVariation |
GWASCAT |
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.
|
23544013 |
2013 |
rs4691139
|
|
G |
0.800 |
GeneticVariation |
GWASCAT |
In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4 × 10(-8), HR = 1.27, 95% CI: 1.17-1.38) and 4q32.3 (rs4691139, P = 3.4 × 10(-8), HR = 1.20, 95% CI: 1.17-1.38).
|
23544013 |
2013 |
rs4691139
|
|
G |
0.800 |
GeneticVariation |
GWASDB |
In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4 × 10(-8), HR = 1.27, 95% CI: 1.17-1.38) and 4q32.3 (rs4691139, P = 3.4 × 10(-8), HR = 1.20, 95% CI: 1.17-1.38).
|
23544013 |
2013 |
rs113488022
|
|
|
0.750 |
GeneticVariation |
BEFREE |
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
|
26490654 |
2015 |
rs113488022
|
|
|
0.750 |
GeneticVariation |
BEFREE |
In this study, we compared detection of the V600E mutation in serous ovarian tumors by VE1 immunostaining and by allele-specific polymerase chain reaction.
|
23089489 |
2013 |
rs113488022
|
|
|
0.750 |
GeneticVariation |
BEFREE |
The presence of the BRAF V600E mutation in SB/LGS ovarian cancer was associated with early stage disease and improved prognosis.
|
22930283 |
2013 |
rs113488022
|
|
|
0.750 |
GeneticVariation |
BEFREE |
No BRAF V600E mutations were detected in nonserous epithelial ovarian tumors.
|
22820660 |
2013 |
rs113488022
|
|
T |
0.750 |
CausalMutation |
CLINVAR |
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
|
22608338 |
2012 |
rs113488022
|
|
T |
0.750 |
CausalMutation |
CLINVAR |
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
|
21639808 |
2011 |
rs113488022
|
|
T |
0.750 |
CausalMutation |
CLINVAR |
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.
|
21683865 |
2011 |
rs113488022
|
|
T |
0.750 |
CausalMutation |
CLINVAR |
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
|
21975775 |
2011 |
rs113488022
|
|
|
0.750 |
GeneticVariation |
BEFREE |
One recurrent somatic mutation, p.V600E, is frequently found in several tumor types, such as melanoma, papillary thyroid carcinoma, colon cancer, and ovarian cancer.
|
20735442 |
2011 |
rs113488022
|
|
T |
0.750 |
CausalMutation |
CLINVAR |
Inhibition of mutated, activated BRAF in metastatic melanoma.
|
20818844 |
2010 |
rs113488022
|
|
T |
0.750 |
CausalMutation |
CLINVAR |
KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
|
19018267 |
2008 |
rs113488022
|
|
T |
0.750 |
CausalMutation |
CLINVAR |
Mutations of the BRAF gene in human cancer.
|
12068308 |
2002 |